SpyGlass Pharma SGP
$30.43 −$0.35 (-1.14%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $30.43 0.00%
Open$30.12
Prev close$30.78
Day range$29.07 – $31.73
Volume108.9K
Market cap$1.02B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$26.25M-136.4% YoY
Net profit-$24.25M-147.1% YoY
Diluted EPS-$0.73-137.3% YoY
Free cash flow-$18.48M-105.5% YoY
Operating cash flow-$16.02M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-114.4%
Return on assets-39.9%
Return on invested capital-120.8%
Current ratio15.24
Liabilities / assets7.0%
Cash & investments$215.76M
Total debt$1.61M
Net cash (debt)$214.15M
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Other Current Liabilities | $6.14M | $3.56M | $2.27M | $3.71M | $3.71M |
| -Short Term Investments | $7.07M | $11.04M | $12.10M | $11.08M | $11.08M |
| -Cash and Cash Equivalents | $208.69M | $223.14M | $238.90M | $96.36M | $96.36M |
| Cash and Cash Equivalents & Short-Term Investments | $215.76M | $234.19M | $251.00M | $107.44M | $107.44M |
| Total Current Assets | $217.92M | $236.46M | $253.36M | $108.77M | $108.77M |
| Total Assets | $226.35M | $243.43M | $258.39M | $115.87M | $115.87M |
| Receivables | $574,000.00 | $678,000.00 | $653,000.00 | $431,000.00 | $431,000.00 |
| Other Current Assets | $1.58M | $1.60M | – | – | – |
| -Accounts Payable | $5.65M | $4.16M | $3.51M | $2.70M | $2.70M |
| Payables | $5.65M | $4.16M | $3.51M | $2.70M | $2.70M |
| Total Current Liabilities | $14.30M | $9.44M | $6.67M | $8.58M | $8.58M |
| Total Liabilities | $15.91M | $11.07M | $8.27M | $214.70M | $214.70M |
| Other Non-Current Assets | $689,000.00 | $759,000.00 | $789,000.00 | $492,000.00 | $492,000.00 |
| Non-Current Deferred Assets | $0.00 | $0.00 | $0.00 | $2.72M | $2.72M |
| -Accumulated Depreciation | -$1.35M | -$1.77M | -$1.43M | -$1.11M | -$1.11M |
| -Gross PPE | $9.10M | $7.99M | $5.67M | $5.01M | $5.01M |
| Net PPE | $7.75M | $6.21M | $4.24M | $3.89M | $3.89M |
| Total Non-Current Assets | $8.43M | $6.97M | $5.02M | $7.10M | $7.10M |
| -Other Receivables | $574,000.00 | $678,000.00 | $653,000.00 | $431,000.00 | $431,000.00 |
| Long Term Debt and Capital Lease Obligation | $1.61M | $1.63M | $1.61M | $1.58M | $1.58M |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Non-Current Liabilities | $1.61M | $1.63M | $1.61M | $206.12M | $206.12M |
| Additional Paid-In Capital | $373.11M | $370.78M | $368.66M | $5.89M | $5.89M |
| Total Equity | $210.44M | $232.36M | $250.11M | -$98.84M | -$98.84M |
| Stockholders' Equity | $210.44M | $232.36M | $250.11M | -$98.84M | -$98.84M |
| Retained Earnings | -$162.67M | -$138.41M | -$118.55M | -$104.73M | -$104.73M |
| Convertible preferred securities | $0.00 | $0.00 | $0.00 | $204.54M | $204.54M |
| -Long Term Capital Lease Obligation | $1.61M | $1.63M | $1.61M | $1.58M | $1.58M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | – | – |
| Prepaid Assets | – | – | $1.71M | $901,000.00 | $901,000.00 |
| -Current Capital Lease Obligation | – | – | – | $0.00 | $0.00 |
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Basic EPS | -$0.73 | -$0.59 | -$0.69 | -$0.39 | -$1.25 |
| Diluted EPS | -$0.73 | -$0.59 | -$0.69 | -$0.39 | -$1.25 |
| Profit from Continuing Operations | -$24.25M | -$19.86M | -$13.82M | -$12.56M | -$39.87M |
| Non-Operating Interest Income | $1.99M | $2.10M | $1.59M | $1.07M | $3.11M |
| Net Non-Operating Interest Income (Expense) | $1.99M | $2.10M | $1.59M | $1.07M | $3.11M |
| Operating Profit | -$26.25M | -$21.97M | -$15.41M | -$13.63M | -$41.45M |
| Research & Development | $10.03M | $10.94M | $8.54M | $7.71M | $29.18M |
| -General & Admin Expense | $16.21M | $11.03M | $6.87M | $5.92M | $12.27M |
| Selling and Admin Expenses | $16.21M | $11.03M | $6.87M | $5.92M | $12.27M |
| Operating Expense | $26.25M | $21.97M | $15.41M | $13.63M | $41.45M |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income to Parent Company | -$24.25M | -$19.86M | -$13.82M | -$12.56M | -$39.87M |
| Pretax Profit | -$24.25M | -$19.86M | -$13.82M | -$12.56M | -$39.87M |
| Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income to Common Stockholders | -$24.25M | -$19.86M | -$13.82M | -$12.56M | -$39.87M |
| Net Profit | -$24.25M | -$19.86M | -$13.82M | -$12.56M | -$39.87M |
| Other Non-Operating Income (Expenses) | – | – | – | $0.00 | -$1.53M |
| Other Income (Expense) | – | – | – | $0.00 | -$1.53M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Free Cash Flow | -$18.48M | -$16.77M | -$14.22M | -$9.76M | -$33.49M |
| Beginning Cash Balance | $223.14M | $238.90M | $96.36M | $106.01M | $16.27M |
| Net Change in Cash | -$14.46M | -$15.76M | $142.54M | -$9.65M | $80.09M |
| Ending Cash Balance | $208.69M | $223.14M | $238.90M | $96.36M | $96.36M |
| -Change in Payables and Accrued Expense | $2.30M | $1.61M | -$347,000.00 | $3.59M | $3.12M |
| -Change in Prepaid Assets | $15,000.00 | $109,000.00 | -$805,000.00 | $338,000.00 | -$186,000.00 |
| -Change in Receivables | $104,000.00 | -$25,000.00 | -$222,000.00 | -$13,000.00 | -$8,000.00 |
| Change in Working Capital | $5.65M | $2.48M | -$1.75M | $2.56M | $2.45M |
| Other Non-Cash Items | -$3,000.00 | $120,000.00 | $32,000.00 | -$480,000.00 | -$209,000.00 |
| Depreciation & Depletion & Amortization | $280,000.00 | $342,000.00 | $318,000.00 | $217,000.00 | $612,000.00 |
| Net Income from Continuing Operations | -$24.25M | -$19.86M | -$13.82M | -$12.56M | -$39.87M |
| Net cash flow from continuing operations | -$16.02M | -$14.84M | -$13.54M | -$9.34M | -$32.70M |
| Operating Cash Flow | -$16.02M | -$14.84M | -$13.54M | -$9.34M | -$32.70M |
| -Change in Other Current Assets | $71,000.00 | $30,000.00 | -$298,000.00 | -$14,000.00 | -$38,000.00 |
| -Change in Other Current Liabilities | $3.16M | $759,000.00 | -$79,000.00 | -$1.34M | -$441,000.00 |
| Net Other Financing Charges | $0.00 | -$18,000.00 | -$2.73M | -$909,000.00 | -$1.47M |
| Proceeds from Stock Option Exercised | $27,000.00 | $31,000.00 | $55,000.00 | $21,000.00 | $170,000.00 |
| Net Preferred Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $127.34M |
| Net Common Stock Issuance | $0.00 | $0.00 | $160.43M | $0.00 | -$1.45M |
| Net Cash Flow from Continuing Financing Activities | $27,000.00 | $13,000.00 | $157.76M | -$888,000.00 | $124.59M |
| Financing Cash Flow | $27,000.00 | $13,000.00 | $157.76M | -$888,000.00 | $124.59M |
| Net Investment Purchase and Sale | $4.00M | $999,000.00 | -$991,000.00 | $995,000.00 | -$11.01M |
| Net PPE Purchase and Sale | -$2.46M | -$1.93M | -$676,000.00 | -$421,000.00 | -$789,000.00 |
| Net Cash Flow from Continuing Investing Activities | $1.54M | -$933,000.00 | -$1.67M | $574,000.00 | -$11.79M |
| Net cash flow from investing | $1.54M | -$933,000.00 | -$1.67M | $574,000.00 | -$11.79M |
| Gain/Loss from Continuing Operations | – | – | – | $1,000.00 | $5,000.00 |
No comments yet — be the first to weigh in on SGP.
Sign in to join the discussion.